Inhibition of P-glycoprotein-mediated multidrug resistance by unfractionated heparin. A new potential chemosensitizer for cancer therapy

Cancer Biology and Therapy

Volumn 4, Issue 3, 2005, Pages 313-317

  Angelini, Antonio ^a   Di Febbo, Concetta ^a   Ciofani, Giuliano ^a   Di Nisio, Marcello ^a   Baccante, Giovanna ^a   Di Ilio, Carmine ^a   Cuccurullo, Franco ^a   Porreca, Ettore ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Calcein AM; Doxorubicin; Heparin; MDA MB321; MDR; MTT; Pgp; UFH; Verapamil

Indexed keywords

BIOLOGICAL MARKER; CALCEIN ACETOXYMETHYL ESTER; CALCIUM CHANNEL BLOCKING AGENT; DOXORUBICIN; ESTER DERIVATIVE; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HEPARIN; UNCLASSIFIED DRUG; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; COMPARATIVE STUDY; COMPETITIVE INHIBITION; CONCENTRATION PROCESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIDRUG RESISTANCE; PROTEIN LOCALIZATION; SENSITIVITY ANALYSIS; SENSITIZATION;

EID: 25144494127     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.3.1503     Document Type: Article

References (30)

1. Smorenburg SM, van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53:93-105.
2. Collen A, Smorenburg SM, Peters E, Lupu F, Koolwijk P, Van Noorden C, van Hinsbergh VW. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000; 60:6196-200.
3. Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 2004; 58:213-9.
4. Endicott JA, Ling VZ. The biochemistry of P-glycoprotein mediated multidrug resistance. Annu Rev Biochem 1989; 58:137-71.
5. Gottesman MM, Pastan I. Biochemistry of multidrug resistence mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385-427.
6. Gottesmann MM, Fojo T, Bates SE. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer 2002; 2:48-58.
7. Fuqua SA, Morett-Rojas IM, Schneider SL, McGuire WL. P-glycoprotein expression in human breast cancer cells. Cancer Res 1987; 47:2103-6.
8. Bradshaw DM, Arceci RJ. Clinical relevance of transmembrane drug efflux as mechanism of multidrug resistance. J Clinical Oncol 1998; 16:3674-90.
9. Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: A meta-analysis MDR1/gp 170 expression and its possible functional significance. J Natl Cancer Inst 1997; 89:917-31.
10. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlympoblastic leukaemia cells at diagnosis. Blood 1992; 79:473-6.
11. Chan HS, Thorner PS, Haddad G, Ling V. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990; 50:2818-22.
12. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84:265-9.
13. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM. Expression of a multidrug resistance gene in human cancer. J Natl Cancer Inst 1989; 81:116-24.
14. Chan HS, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H, Ling V. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 1991; 325:1608-14.
15. Larkin A, O'Driscoll L, Kennedy S, Purcell R, Moran E, Crown J, Parkinson M, Clynes M. Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: A prognostic study. Int J Cancer 2004; 112:286-94.
16. Baekeland MM, Holm R, Nesland JM, Trope CG, Kristensen GB. P-glycoprotein expression is a marker for chemotherapy resistance and progress in advanced ovarian cancer. Anticancer Res 2000; 20:1061-7.
17. Robert J. Multidrug resistance and its reversal. General review of fundamental aspects. Ann Biol Clin 1996; 54:3-8.
18. Sarkadi B, Müller M. Search for specific inhibitors of multidrug resistance in cancer. Seminars in Cancer Biology 1997; 8:171-82.
19. Cailleau R, Young R, Olive M, Reeves Jr WJ. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974; 53:661-74.
20. Hollo Z, Homolya L, Davis CW, Sarkadi B. Calcein accumulation as a fluorometric functional assay of the multidrug transporter. Biochim Biophys Acta 1994; 1191:384-8.
21. Szakacs G, Jakab K, Antal F, Sarkadi B. Diagnostics of multidrug resistance in cancer. Phatol Oncol Res 1998; 4:251-7.
22. Karaszi E, Jakab K, Homolya L, Szakacs G, Hollo Z, Telek B, Kiss A, Rejto L, Nahajevszky S, Sarkadi B, Kappelmayer J. Calcein assay for multidrug resistance reliably predicts therapy response and survival rate in acute myeloid leukaemia. British J Haematol 2001; 112:308-14.
23. Hongo T, Fujii Y, Igarashi Y. An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia. Cancer 1989; 65:1263-72.
24. Lambert E, Rees JK, Twentyman PR. Resistance circumvention strategies tested in clinical leukaemia specimens using the MTT colorimetric assay. Leukemia 1992; 6:1063-71.
25. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhancing cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41:1967-72.
26. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003; 8:411-24.
27. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000; 11:265-83.
28. Tan B, Piwnica WD, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol 2000; 12:450-8.
29. Thomas H, Coley HM. Overcoming multidrug resistance in cancer: An update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003; 10:159-65.
30. Ross DD. Modulation of drug resistance transporters as a strategy for the myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17:641-51.